Tejnaksh Healthcare Ltd Upgraded to Sell on Technical Improvement Despite Weak Fundamentals

Quality Assessment: Weak Profitability and Flat Financials

Tejnaksh Healthcare’s quality metrics remain subdued, reflecting ongoing operational challenges. The company reported flat financial performance in Q3 FY25-26, with no significant growth in revenues or profits. Over the past five years, operating profits have declined at a compounded annual growth rate (CAGR) of -5.68%, signalling deteriorating core business strength.

Return on Equity (ROE) averages 9.52%, indicating low profitability relative to shareholders’ funds. This figure is below industry averages, suggesting inefficiencies in capital utilisation. Additionally, the company’s debtors turnover ratio for the half-year period stands at a low 4.87 times, highlighting potential issues in receivables management and cash flow conversion.

These factors contribute to a weak fundamental quality grade, which remains a significant concern despite the recent rating upgrade.

Valuation: Attractive but Reflective of Risks

On valuation grounds, Tejnaksh Healthcare presents a mixed picture. The stock trades at a price-to-book (P/B) ratio of 1.1, which is considered very attractive relative to its peers in the healthcare services sector. This discount suggests the market is pricing in the company’s operational risks and weak growth prospects.

However, the company’s ROE of 6.3% further supports the notion of undervaluation, as it implies the stock is trading below its intrinsic value based on profitability metrics. Despite this, the stock’s long-term underperformance against benchmarks such as the BSE500 and Sensex tempers enthusiasm. Over the last one year, the stock has generated a negative return of -38.60%, while profits have declined by -41.2%, underscoring the valuation discount’s justification.

Financial Trend: Flat to Negative Performance Persists

Financial trends for Tejnaksh Healthcare remain lacklustre. The company’s stock return has consistently underperformed the Sensex and BSE500 indices across multiple time horizons. For instance, over the last one year, the stock declined by -38.60%, while the Sensex gained 2.71%. Over three and five years, the stock’s returns were -66.11% and -61.23%, respectively, compared to Sensex returns of 28.58% and 49.70%.

Profitability has also deteriorated, with a -41.2% fall in profits over the past year. This weak financial trend is compounded by flat quarterly results and poor operational metrics, signalling limited near-term recovery prospects.

Technical Analysis: Key Driver of Rating Upgrade

The primary catalyst for the upgrade from Strong Sell to Sell is an improvement in technical indicators. The technical trend has shifted from bearish to mildly bearish, reflecting a modest positive momentum in the stock price.

Key technical signals include a mildly bullish Moving Average Convergence Divergence (MACD) on both weekly and monthly charts, indicating potential upward momentum. However, other indicators such as Bollinger Bands and Dow Theory remain mildly bearish on weekly and monthly timeframes, suggesting caution.

Moving averages on the daily chart are mildly bearish, while the Know Sure Thing (KST) oscillator remains bearish on weekly and monthly scales. The Relative Strength Index (RSI) shows no clear signal, indicating a neutral momentum stance.

Despite mixed signals, the overall technical picture has improved sufficiently to warrant a rating upgrade, reflecting a potential bottoming out of the stock price after recent declines.

Price and Market Capitalisation Context

Tejnaksh Healthcare is classified as a micro-cap stock, with a current price of ₹14.49 as of 13 March 2026, up 8.30% from the previous close of ₹13.38. The stock’s 52-week high and low stand at ₹24.77 and ₹12.10, respectively, indicating significant volatility and a wide trading range.

Today’s trading range was between ₹13.45 and ₹14.71, reflecting active investor interest amid the rating change. Despite the recent price uptick, the stock remains well below its 52-week high, consistent with its weak long-term performance.

Shareholding and Industry Position

The majority shareholding in Tejnaksh Healthcare is held by promoters, which often provides stability but also concentrates control. The company operates within the hospital and healthcare services industry, a sector that has seen mixed performance amid evolving healthcare demands and regulatory challenges.

Given its micro-cap status and weak financial trends, Tejnaksh Healthcare faces stiff competition from larger, better-capitalised peers. Its valuation discount partly reflects these structural challenges.

Investment Outlook and Conclusion

While the upgrade from Strong Sell to Sell signals a modest improvement in technical momentum, fundamental weaknesses remain pronounced. The company’s flat financial performance, declining profitability, and persistent underperformance relative to benchmarks caution investors against aggressive positioning.

Valuation metrics suggest the stock is attractively priced, but this is largely due to the market discounting ongoing risks. Investors should weigh the improved technical signals against the weak quality and financial trends before considering exposure.

In summary, Tejnaksh Healthcare Ltd’s rating upgrade reflects a technical rebound rather than a fundamental turnaround. The stock remains a high-risk proposition within the healthcare services micro-cap space, warranting a Sell rating until more robust financial improvements materialise.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →